Rapid Non-invasive prenatal testing (NIPT) via digital counting of fetal DNA
|Coordinator||OLINK BIOSCIENCE AB|
|Funding from Vinnova||SEK 1 000 000|
|Project duration||June 2017 - June 2018|
|Venture||Swelife and Medtech4Health- Project proposals to improve health|
|Call||SWElife and Medtech4Health- Project proposals to improve health 2017|
Purpose and goal
Our goal was to develop a fast, inexpensive and safe fetal test for chromosomal aberrations based on unique technology detecting circulating DNA in blood. The technology has been optimized and proven to work on blood samples and with standard equipment available in many laboratories. Researchers in bioinformatics have designed a data script for probe design that identifies target sequences in DNA.
Expected results and effects
The molecular technology is optimized in a model system and is also tested on blood samples. The method can be used for fetal testing but also for patient follow up and therapy selection for cancer treatment. The bioinformatic script for probe design can also be applied to other technologies that require advanced, large-scale probe design.
Planned approach and implementation
Olink Bioscience has developed and optimized the molecular technology. Researchers in bioinformatics from Uppsala University have developed the data script to find target sequences in the genome. Olink Bioscience has also further developed the business plan and has been initiated collaboration with instrument manufacturers, end users, clinicians, regulatory expertise and IP advisors to define market opportunities.